Latest News and Press Releases

-Additional data from the PRIMROSE Phase 3 studies of linzagolix featured in four posters. Oral presentation took place on May 8, 2022 at 9:15am PT/12:15pm ET- GENEVA, Switzerland May 9, 2022 –...

-Additional data from the PRIMROSE Phase 3 studies of linzagolix featured in four posters. Oral presentation took place on May 8, 2022 at 9:15am PT/12:15pm ET- GENEVA, Switzerland May 9, 2022 –...

  -Symposium on oral GnRH antagonists and personalized therapeutic approaches for women with uterine fibroids to be hosted Friday, December 10 at 1 p.m. CET- -52-Week Data from the Phase 3...

FDA Accepts NDA for Linzagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids   Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA,...

 -PRIMROSE 1 76-week results confirm PRIMROSE 2 data showing sustained post-treatment effects and evidence of bone mineral density (BMD) recovery following 52 weeks of treatment- -Results continue...

-Long-term follow-up study to evaluate bone mineral density in women completing at least 20 weeks of treatment in Phase 3 PRIMROSE 1 or PRIMROSE 2 -   GENEVA, Switzerland and BOSTON, MA – April...

  PRIMROSE 1 52-week results confirm the sustained efficacy and continued safety of linzagolix (Yselty®), with a potential best-in-class high-dose option (200 mg with add-back therapy [ABT]) Show...

  If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options for the management of uterine fibroids: 100 mg once daily for women with a contraindication to or who...

 Geneva, Switzerland and Boston, MA – 2 November, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve...

  PRIMROSE 1 achieved statistically significant and clinically meaningful results across primary and key secondary endpoints at week 24  PRIMROSE 2 results demonstrate sustained efficacy and...